The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Open accessAbstract
BACKGROUND: Extramedullary disease is an uncommon manifestation in multiple myeloma and can either accompany newly diagnosed disease or develop with disease progression or relapse. We evaluated the impact of this disease feature on patients' outcome in the context of novel agents. DESIGN AND METHODS: We analyzed clinical and biological features of extramedullary disease in 936 patients with multiple myeloma enrolled in Total Therapy protocols, 240 patients in non-Total Therapy protocols, and 789 non-protocol patients, all of whom had baseline positron emission tomography scans to document extramedullary disease at diagnosis and its subsequent development at the time of disease progression or relapse. RESULTS: The most common sites for extramedullary disease at diagnosis were skin and soft tissue whereas liver involvement was the striking feature in extramedullary disease at disease relapse or progression. Regardless of therapy, extramedullary disease was associated with shorter progression-free and overall survival, as well as the presence of anemia, thrombocytopenia, elevated serum lactate dehydrogenase, cytogenetic abnormalities, and high-risk features in 70-and 80-gene risk models in univariate analysis. Multivariate analysis with logistic regression revealed that this disease feature was more prevalent in patients with an elevated centrosome index, as determined by gene expression profiling, as well as in myeloma molecular subtypes that are more prone to relapse. These include the MF subtype (also called the "MAF" subtype, associated with over-expression of the MAF gene seen with chromosome translocation 14;16 or 14;20) and the PR subtype (also called the "Proliferation" subtype, associated with overexpression of pro-proliferative genes). CONCLUSIONS: These data show that extramedullary disease is more prevalent in genomically defined high-risk multiple myeloma and is associated with shorter progression-free survival and overall survival, even in the era of novel agents. All clinical trials included in the analyses were registered with www.clinicaltrials.gov (NCT00083551, NCT00083876, NCT00081939, NCT00572169, NCT00644228,NCT00002548,NCT00734877).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 888
Self-citationZhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1745 · Cited by 638
Self-citationZamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-361386 · Cited by 531
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Self-citationVarettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 487
Bladé, J., Fernández de Larrea, C., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9290 · Cited by 387
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Martinez-Lopez, J., Blade, J., Mateos, M.-V., Grande, C., Alegre, A., García-Laraña, J., Sureda, A., de la Rubia, J., Conde, E., Martinez, R., et al. (2011) · Blood · doi:10.1182/blood-2011-01-332320 · Cited by 206
Bladé, J., Kyle, R. A., & Greipp, P. R. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.5191061.x · Cited by 201
Bladé, J., Lust, J. A., & Kyle, R. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2398 · Cited by 198
Rasmussen, T., Kuehl, M., Lodahl, M., Johnsen, H. E., & Dahl, I. M. S. (2005) · Blood · doi:10.1182/blood-2004-03-0833 · Cited by 163
Barlogie, B., Attal, M., Crowley, J. J., van Rhee, F., Szymonifka, J. D., Moreau, P., Durie, B. G. M., & Harousseau, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6081 · Cited by 159
Self-citationAvet‐Loiseau, H., Soulier, J., Fermand, J., Yakoub‐Agha, I., Attal, M., Hulin, C., Garderet, L., Belhadj, K., Dorvaux, V., Minvielle, S., et al. (2010) · Leukemia · doi:10.1038/leu.2009.273 · Cited by 138
Dewald, G. W., Therneau, T. M., Larson, D. R., Lee, Y. K., Fink, S. R., Smoley, S. A., Paternoster, S. F., Adeyinka, A., Ketterling, R. P., Dyke, D. L. V., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1981 · Cited by 127
The impact of extramedullary disease at presentation on the outcome of myeloma
Wu, P., Davies, F. E., Boyd, K. D., Thomas, K., Dines, S., Saso, R. M., Potter, M. N., Ethell, M. E., Shaw, B. E., & Morgan, G. J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802657751 · Cited by 115
The molecular characterization and clinical management of multiple myeloma in the post-genome era
Zhou, Y., Barlogie, B., & Shaughnessy, J. D. (2009) · Leukemia · doi:10.1038/leu.2009.160 · Cited by 108
Self-citationClinical implication of centrosome amplification in plasma cell neoplasm
Chng, W. J., Ahmann, G. J., Henderson, K. J., Santana-Dávila, R., Greipp, P. R., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Kumar, S. K., Rajkumar, S. V., et al. (2005) · Blood · doi:10.1182/blood-2005-09-3810 · Cited by 96
A Long-Term Study of Prognosis on Monoclonal Gammopathy of Undetermined Significance.
Case, D. C., & Boyd, M. A. (2006) · Blood · doi:10.1182/blood.v108.11.4994.4994 · Cited by 92
Usmani, S. Z., Nair, B. P., Qu, P., Hansen, E., Zhang, Q., Petty, N. M., Waheed, S., Shaughnessy, J. D., Alsayed, Y. M., Heuck, C. J., et al. (2012) · Leukemia · doi:10.1038/leu.2012.107 · Cited by 90
Self-citationKühnemund, A., Liebisch, P., Bauchmüller, K., Hausen, A. Z., Veelken, H., Wäsch, R., & Engelhardt, M. M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0470-7 · Cited by 72
P53 deletion may drive the clinical evolution and treatment response in multiple myeloma
López‐Anglada, L., Gutierrez, N. C., Garcı́a, J. L., Mateos, M., Flores, T., & Miguel, J. F. S. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01399.x · Cited by 54
Rosiñol, L., Cibeira, M. T., Martínez‐López, J., Mateos, M., Oriol, A., Terol, M. J., García‐Laraña, J., Hernández‐Maraver, D., de la Rubia, J., Sureda, A. M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.130.130 · Cited by 46
Light Chain Escape in Multiple Myeloma
Dejoie, T., Fouquet, G., Hulin, C., Roussel, M., Hébraud, B., Karlin, L., Kolb, B., Araujo, C., Meuleman, N., Tiab, M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112396 · Cited by 11
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationDiagnosis and Management of Multiple Myeloma: A Review
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L. A., Tuazon, S., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,029
Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengass, J., Engelhardt, M., Usmani, S. Z., Vesole, D. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30189-4 · Cited by 544
Self-citationD'Agostino, M., Cairns, D. A., Lahuerta, J. J., Wester, R., Bertsch, U., Waage, A., Zamagni, E., Mateos, M.-V., Dall'Olio, D., van de Donk, N. W. C. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02614 · Cited by 429
Extramedullary disease in multiple myeloma: a systematic literature review
Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319
Self-citation
Metadata
- Authors
- Usmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., Van Rhee, F., Crowley, J., & Barlogie, B.
- Venue
- Haematologica
- Published
- 2012-06-11
- Volume
- 97
- Issue
- 11
- Pages
- 1761-1767
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2104149194
- Cited by
- 394
- References
- 26
- FWCI
- 13.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.